search
Back to results

A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease

Primary Purpose

Alzheimer Disease

Status
Recruiting
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
EX039
Placebo
Sponsored by
Excelsior
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 50-80 years.
  • Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011)
  • Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-26.
  • Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of
  • Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria:

    • AST, ALT level ≦ upper limit of normal
    • Creatine Kinase (CK) concentration more than 3 times upper limit of normal
    • Serum creatinine level ≦ upper limit of normal
    • HbA1c more than 8.0
  • Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities.
  • Cognitive deficits caused impairment in social or occupational function.
  • Disease progression with gradual and continued decline from a previous level of functioning.
  • Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control.
  • Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study.

Exclusion Criteria:

  • Having other causes of dementia.
  • Having substantial concomitant cerebrovascular disease (defined by a history of a stroke

    / intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.

  • Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  • Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement:

    • Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension.
    • Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV.
    • Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
    • Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism.
    • Unstable/Uncontrolled major depression.
    • Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis).
    • Significant pulmonary disease predisposing to hypoxia.
    • Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease)
  • Any other psychiatric disorders such as schizophrenia, or mental retardation.
  • Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  • Hachinski Ischemic Score > 4
  • Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator)
  • Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
  • Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole.

Sites / Locations

  • National Taiwan University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1000 mg

750 mg

placebo

Arm Description

The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day

The recruited patient randomly assigned to this arm will take 750 mg EX039 per day

The recruited patient randomly assigned to this arm will take placebo per day

Outcomes

Primary Outcome Measures

Change in Alzheimer's Disease Assessment Scale-cognitive
Mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale measured at the end of week 28. Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.
Change in Clinical Dementia Rating-Sum of Boxes
Mean change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB). measured at the end of week 28. Total scores range from 0 to 18, with higher scores indicating more worsening.

Secondary Outcome Measures

Change in Clinician's Interview-Based Impression of Change Plus Caregiver Input
Scorings of Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) at the end of week 4, 12, 20, and 28.
Incidence of Treatment-Emergent Adverse Events
To assess the safety and tolerability of EX039
Responder rate assessment
The percentage of the recruited subjects whose mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) measured at the end of week 28 is improved (≧4) without deterioration of CDR-SB and CIBIS-Plus

Full Information

First Posted
March 14, 2022
Last Updated
September 5, 2023
Sponsor
Excelsior
Collaborators
Formosa Biomedical Technology Corp.
search

1. Study Identification

Unique Protocol Identification Number
NCT05413655
Brief Title
A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
Official Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects With Mild Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 8, 2022 (Actual)
Primary Completion Date
August 2025 (Anticipated)
Study Completion Date
February 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Excelsior
Collaborators
Formosa Biomedical Technology Corp.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1000 mg
Arm Type
Experimental
Arm Description
The recruited patient randomly assigned to this arm will take 1000 mg EX039 per day
Arm Title
750 mg
Arm Type
Experimental
Arm Description
The recruited patient randomly assigned to this arm will take 750 mg EX039 per day
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
The recruited patient randomly assigned to this arm will take placebo per day
Intervention Type
Drug
Intervention Name(s)
EX039
Intervention Description
The dosage form of EX039 is the capsule for oral use
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The dosage form of Placebo is the capsule for oral use
Primary Outcome Measure Information:
Title
Change in Alzheimer's Disease Assessment Scale-cognitive
Description
Mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale measured at the end of week 28. Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment.
Time Frame
Week 28
Title
Change in Clinical Dementia Rating-Sum of Boxes
Description
Mean change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB). measured at the end of week 28. Total scores range from 0 to 18, with higher scores indicating more worsening.
Time Frame
Week 28
Secondary Outcome Measure Information:
Title
Change in Clinician's Interview-Based Impression of Change Plus Caregiver Input
Description
Scorings of Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) at the end of week 4, 12, 20, and 28.
Time Frame
Week 4, 12, 20, 28
Title
Incidence of Treatment-Emergent Adverse Events
Description
To assess the safety and tolerability of EX039
Time Frame
Week 30
Title
Responder rate assessment
Description
The percentage of the recruited subjects whose mean change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) measured at the end of week 28 is improved (≧4) without deterioration of CDR-SB and CIBIS-Plus
Time Frame
Week 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 50-80 years. Clinical diagnosis of probable mild Alzheimer disease dementia based on National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA criteria, 2011) Last time (which must be within 3 months ) of Mini Mental State Exam (MMSE) between 10-26. Last time (which must be within 3 months) of Clinical Dementia Rating (CDR) score of 1. Physically healthy and all laboratory assessments (including hematology, chemistry, urinalysis and electrocardiograph) are within normal range or meet the following criteria: AST, ALT level ≦ upper limit of normal Creatine Kinase (CK) concentration more than 3 times upper limit of normal Serum creatinine level ≦ upper limit of normal HbA1c more than 8.0 Complaints of subjective memory impairment and cognitive disturbances by patients themselves or caregivers, including memory loss and at least one of the following cognitive disturbances: language, perceptual skills, attention, constructive abilities, orientation, problem solving, functional abilities. Cognitive deficits caused impairment in social or occupational function. Disease progression with gradual and continued decline from a previous level of functioning. Female subjects must be of non-childbearing potential (greater than 1 year without menstrual period in the absence of hormone replacement therapy) or surgically sterile. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test and must not be lactating at screening visit. Female subjects of childbearing potential and who are sexually active are required to practice adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control. Has sufficient education equivalent to elementary education to communicate effectively and were capable of completing the assessments of the study. Exclusion Criteria: Having other causes of dementia. Having substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years. Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement: Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension. Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV. Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease). Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism. Unstable/Uncontrolled major depression. Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis). Significant pulmonary disease predisposing to hypoxia. Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease) Any other psychiatric disorders such as schizophrenia, or mental retardation. Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior). Hachinski Ischemic Score > 4 Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator) Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed. Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cliff Lin
Phone
+886-972821234
Email
cliff.lin@excelsiorgroup.com.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ching-Kuan Liu, Dr.
Organizational Affiliation
Kaohsiung Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pei-Ling Peng
Phone
886-2-23123456
Ext
65340
Email
ho-ling@yahoo.com.tw

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There won't be any individual participant data shared to other researchers.

Learn more about this trial

A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease

We'll reach out to this number within 24 hrs